COMETRIQ (Exelixis, Inc.)


Welcome to the PulseAid listing for the COMETRIQ drug offered from Exelixis, Inc.. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Exelixis, Inc.
NON-PROPRIETARY NAME: cabozantinib
SUBSTANCE NAME: CABOZANTINIB S-MALATE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: CAPSULE
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2012-11-29
END MARKETING DATE: 0000-00-00


COMETRIQ HUMAN PRESCRIPTION DRUG Details:

Item DescriptionCOMETRIQ from Exelixis, Inc.
LABELER NAME: Exelixis, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 20(mg/1)
START MARKETING DATE: 2012-11-29
END MARKETING DATE: 0000-00-00
PRODUCT ID: 42388-013_fc9853b8-b4a4-42b7-915f-a97a80586080
PRODUCT NDC: 42388-013
APPLICATION NUMBER: NDA203756

Other CABOZANTINIB S-MALATE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Exelixis, Inc.COMETRIQ